Table 1. Clinical data of 98 patients with metastatic breast cancer.
| Clinical features | Combination group, n (%) | X maintenance group, n (%) |
|---|---|---|
| Age | ||
| ≥60 years | 18 (18.4) | 13 (26.0) |
| <60 years | 80 (81.6) | 37 (74.0) |
| Hormone receptor | ||
| Positive | 53 (54.1) | 31 (62.0) |
| Negative | 45 (45.9) | 19 (38.0) |
| Her-2 | ||
| Positive | 43 (43.9) | 22 (44.0) |
| Negative | 55 (56.1) | 28 (56.0) |
| Previous treatment | ||
| First-line | 53 (54.1) | 30 (60.0) |
| Second-line and above | 45 (45.9) | 20 (40.0) |
| Metastatic sites | ||
| Viscera | 77 (78.6) | 39 (78.0) |
| Non-viscera | 21 (21.4) | 11 (22.0) |
| DFS | ||
| >2 years | 44 (44.9) | 23 (46.0) |
| ≤2 years | 54 (55.1) | 27 (54.0) |
X, capecitabine; DFS, disease-free survival.